Correction: Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma

Zhou J, Wu Z, Zhang Z, et al. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut 2022;71:665–75. doi:10.1136/gutjnl-2020-323276 Following publication of the original article, authors identified an error in figure 3B, specifically: TE9 cell line total HER3, total AKT and total ERK lanes appear to be misused. The correct figure is presented below. This correction does not affect the result and conclusions of the study. We apologise for this error and any inconvenience caused. Figure 3 Pan ERBB and CDK4/6 pathway dual inhibition demonstrated efficacy in ESCC. (A) Images showing crystal violet staining of representative squamous carcinoma cell lines on treatment with afatinib (20 nM), palbociclib (500 nM), the combination or with DMSO control for 7–10 days. Data from one representative experiment are presented (n=2). (B) Immunoblot analysis of genes involved in ERBB signalling pathway and cell-cycle pathway in TE9, TE11 and KYSE180 cells...
Source: Gut - Category: Gastroenterology Tags: Open access, Gut Correction Source Type: research